These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35940647)

  • 1. Loss of Heterozygosity for Tuberous Sclerosis Complex and Mammalian Target of Rapamycin Signaling: The Keys to Understanding the Pathogenesis of Diffuse Cystic Lung Diseases?
    O'Callaghan M; McCarthy C
    Chest; 2022 Aug; 162(2):279-280. PubMed ID: 35940647
    [No Abstract]   [Full Text] [Related]  

  • 2. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
    Curatolo P
    Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tuberous sclerosis complex 2 loss of heterozygosity in patients with lung disease and cancer.
    Zhang L; Pacheco-Rodriguez G; Steagall WK; Kato J; Haughey M; Fontana JR; Manganiello VC; Moss J
    Am J Respir Crit Care Med; 2015 Feb; 191(3):352-5. PubMed ID: 25635494
    [No Abstract]   [Full Text] [Related]  

  • 4. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.
    Bissler JJ; McCormack FX; Young LR; Elwing JM; Chuck G; Leonard JM; Schmithorst VJ; Laor T; Brody AS; Bean J; Salisbury S; Franz DN
    N Engl J Med; 2008 Jan; 358(2):140-51. PubMed ID: 18184959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tuberous sclerosis complex.
    Hasbani DM; Crino PB
    Handb Clin Neurol; 2018; 148():813-822. PubMed ID: 29478616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is mTOR inhibition a systemic treatment for tuberous sclerosis?
    Moavero R; Coniglio A; Garaci F; Curatolo P
    Ital J Pediatr; 2013 Sep; 39():57. PubMed ID: 24044547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex.
    Sato A; Kasai S; Kobayashi T; Takamatsu Y; Hino O; Ikeda K; Mizuguchi M
    Nat Commun; 2012; 3():1292. PubMed ID: 23250422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
    MacKeigan JP; Krueger DA
    Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mammalian target of rapamycin inhibitors in a patient with polycystic kidney disease-1-tuberous sclerosis-2 contiguous gene syndrome.
    Anandh U; Chandrasekar G; Agarwal V
    Saudi J Kidney Dis Transpl; 2018; 29(6):1475-1479. PubMed ID: 30588981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tuberous sclerosis complex, mTOR, and the kidney: report of an NIDDK-sponsored workshop.
    Henske EP; Rasooly R; Siroky B; Bissler J
    Am J Physiol Renal Physiol; 2014 Feb; 306(3):F279-83. PubMed ID: 24226526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabidiol Elevates Mechanistic Target of Rapamycin Inhibitor Levels in Patients With Tuberous Sclerosis Complex.
    Ebrahimi-Fakhari D; Agricola KD; Tudor C; Krueger D; Franz DN
    Pediatr Neurol; 2020 Apr; 105():59-61. PubMed ID: 31924480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
    Chan JA; Zhang H; Roberts PS; Jozwiak S; Wieslawa G; Lewin-Kowalik J; Kotulska K; Kwiatkowski DJ
    J Neuropathol Exp Neurol; 2004 Dec; 63(12):1236-42. PubMed ID: 15624760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel TSC2 mutation in a patient with pulmonary tuberous sclerosis: lack of loss of heterozygosity in a lung cyst.
    Zhang H; Yamamoto T; Nanba E; Kitamura Y; Terada T; Akaboshi S; Yuasa I; Ohtani K; Nakamoto S; Takeshita K; Ohno K
    Am J Med Genet; 1999 Feb; 82(5):368-70. PubMed ID: 10069705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mammalian target of rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy.
    Yu J; Parkhitko AA; Henske EP
    Proc Am Thorac Soc; 2010 Feb; 7(1):48-53. PubMed ID: 20160148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tuberous sclerosis-associated epilepsy and intellectual disability: what role does the mammalian target of rapamycin pathway play?
    Curatolo P
    Dev Med Child Neurol; 2020 Mar; 62(3):269. PubMed ID: 31591705
    [No Abstract]   [Full Text] [Related]  

  • 16. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb.
    Tee AR; Manning BD; Roux PP; Cantley LC; Blenis J
    Curr Biol; 2003 Aug; 13(15):1259-68. PubMed ID: 12906785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders.
    Franz DN; Capal JK
    Orphanet J Rare Dis; 2017 Mar; 12(1):51. PubMed ID: 28288694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Restoration of Normal Cerebral Oxygen Consumption with Rapamycin Treatment in a Rat Model of Autism-Tuberous Sclerosis.
    Chi OZ; Wu CC; Liu X; Rah KH; Jacinto E; Weiss HR
    Neuromolecular Med; 2015 Sep; 17(3):305-13. PubMed ID: 26048361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma.
    Lu KH; Wu W; Dave B; Slomovitz BM; Burke TW; Munsell MF; Broaddus RR; Walker CL
    Clin Cancer Res; 2008 May; 14(9):2543-50. PubMed ID: 18451215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits.
    Feliciano DM; Lin TV; Hartman NW; Bartley CM; Kubera C; Hsieh L; Lafourcade C; O'Keefe RA; Bordey A
    Int J Dev Neurosci; 2013 Nov; 31(7):667-78. PubMed ID: 23485365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.